Cyanate attenuates insulin secretion in cultured pancreatic β cells

Molecular Medicine Reports

Volumn 5, Issue 6, 2012, Pages 1461-1464

  Ha, Eunyoung ^a  

^a Keimyung University   (South Korea)

Author keywords

Cyanate; Insulin; Pancreatic cells; Reactive oxygen species

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYANIC ACID; INSULIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE ANALYSIS; INHIBITION KINETICS; INSULIN RELEASE; OXIDATION; PANCREAS ISLET BETA CELL;

ANIMALS; APOPTOSIS; CELL LINE; CYANATES; INSULIN; INSULIN-SECRETING CELLS; RATS; REACTIVE OXYGEN SPECIES;

EID: 84860786292     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.837     Document Type: Article

References (24)

1. Marier JR and Rose D: Determination of cyanate, a study of its accumulation in aqueous solutions of urea. Anal Biochem 7: 304-314, 1964.
2. Fluckiger R, Harmon W, Meier W, et al: Hemoglobin carbamylation in uremia. N Engl J Med 304: 823-827, 1981. (Pubitemid 11147484)
3. Kraus LM, Jones MR and Kraus AP Jr: Essential carbamoyl-amino acids formed in vivo in patients with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, identification, and quantitation. J Lab Clin Med 131: 425-431, 1998. (Pubitemid 28259758)
4. Roxborough HE, Millar CA, McEneny J and Young IS: Carbamylation inhibits the ferroxidase activity of caeruloplasmin. Biochem Biophys Res Commun 214: 1073-1078, 1995.
5. Erill S, Calvo R and Carlos R: Plasma protein carbamylation and cecreased acidic drug protein binding in uremia. Clin Pharmacol Ther 27: 612-618, 1980. (Pubitemid 10105592)
6. Hörkkö S, Huttunen, Kervinen K and Kesäniemi YA: Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 24: 105-113, 1994. (Pubitemid 24222972)
7. Kraus LM and Kraus AP Jr: Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 78: S102-S107, 2001. (Pubitemid 32144080)
8. Wang Z, Nicholls SJ, Rodriguez ER, et al: Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13: 1176-1184, 2007. (Pubitemid 47530630)
9. Eiserich JP, Baldus S, Brennan ML, et al: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296: 2391-2394, 2002. (Pubitemid 34734213)
10. Zhang C, Yang J, Jacobs JD and Jennings LK: Interaction of myeloperoxidase with vascular NAD(P)H oxidases derived reactive oxygen species in the vasulature: implications for vascular diseases. Am J Physiol Heart Circ Physiol 285: H2563-H2572, 2003.
11. Heilman K, Zilmer M, Zilmer K, et al: Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Dabetes Res Clin Pract 84: 168-173, 2009.
12. Stim J, Shaykh M, Anwar F, et al: Factors determining hemoglobin carbamylation in renal failure. Kidney Int 48: 1605-1610, 1995.
13. Balion CM, Draisey TF and Thibert RJ: Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int 53: 488-495, 1998. (Pubitemid 28097868)
14. Nilsson L, Lundquist P, Kagedal B and Larsson R: Plasma cyanate concentrations in chronic renal failure. Clin Chem 42: 482-483, 1996.
15. Asci G, Basci A, Shah SV, et al: Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecules expression of human coronary artery smooth muscle cells. Nephrology 13: 480-486, 2008.
16. Jaisson S, Sartelet H, Perreau C, et al: Involvement of lysine 1047 in type I collagen-mediated activation of polymorphonuclear neutrophils. FEBS J 275: 3226-3235, 2008. (Pubitemid 351743596)
17. Son JN, Lho Y, Shin S, et al: Carbamylated low-density lipoprotein increases reactive oxygen species (ROS) and apoptosis via lectin-like oxidized LDL receptor (LOX-1) mediated pathway in human umbilical vein endothelial cells. Int J Cardiol 146: 428-430, 2011.
18. Ha E, Bang JH, Son JN, et al: Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma. Mol Med Report 3: 275-279, 2010.
19. Nicholls SJ and Hazen SL: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25: 1102-1111, 2005. (Pubitemid 40776595)
20. Hazen SL and Heineche JW: 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99: 2075-2081, 1997. (Pubitemid 27203762)
21. Podrez EA, Schmitt K, Hoff HF and Hazen SL: Myeloperoxidase-generated reactive nitrogen species convert LDL intoan atherogenic form in vitro. J Clin Invest 103: 1547-1560, 1999.
22. Asselberges FW, Reynolds WF, Cohen-Tervaert JW, et al: Myeloperoxidas polymorphism related to cardiovascular events in coronary artery disease. Am J Med 116: 429-430, 2004. (Pubitemid 38299491)
23. McMillen TS, Heinecke JW and LeBoeuf RC: Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111: 2798-2804, 2005. (Pubitemid 40791552)
24. Wiersma JJ, Meuwese MC, van Miert JN, et al: Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. Med Sci Monit 14: CR406-CR410, 2008.